ArticleCardiovascular engineering and technology2025
The Efficacy of Cardiac Contractility Modulation for Treating Patients with Heart Failure.
Article in Cardiovascular engineering and technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHeart failure (HF) is still a leading cause of mortality and morbidity despite considerable advances in therapy. This study aimed to evaluate the efficacy of cardiac contractility modulation (CCM) for treating Chinese patients with HF.
methodsThis retrospective study included six HF patients who had New York Heart Association (NYHA) class II or III and received CCM implantation at the First Affiliated Hospital of Soochow University from May 2022 to May 2023. Assessments were conducted before and after 12 months of CCM treatment to evaluate the left ventricular ejection fraction (LVEF), the left ventricular end-diastolic dimension (LVEDD), the left atrium diameter (LAD), and cardiac function.
resultsAfter the 12-month follow-up, all outcome measures showed improvement: the LVEF increased from (27 ± 4.73) % to (39.67 ± 7.06) %, the LVEDD decreased from (70.33 ± 1.97) mm to (64.83 ± 3.71) mm, and the LAD decreased from (52.83 ± 7.14) mm to (47.00 ± 7.48) mm. All patients reached NYHA functional class II.
conclusionsThe findings from this small study suggest that CCM therapy can enhance the cardiac functional status, improve LVEF, and reverse ventricular remodeling.
Indexed as
Identifiers
39586917What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.